Enhancing programmed cell death protein 1 axis inhibition in head and neck squamous cell carcinoma: combination immunotherapy

Head and neck cancers represent the sixth most common malignancy worldwide and are projected to cause approximately 54,000 new cases and 11,000 deaths in the US in 2021 [1]. Head and neck squamous cell carcinoma (HNSCC) accounts for 90% of all head and neck cancers. Most HNSCC patients are diagnosed with locally advanced disease [2,3]. Despite advances in multimodality approaches, more than 50% of patients with locally advanced disease relapse and the median overall survival (OS) for patients with recurrent/metastatic (R/M) disease is only 10-13 months [2-5].
Source: Cancer Treatment Reviews - Category: Cancer & Oncology Authors: Tags: New Drugs Source Type: research